摘要
目的观察NE与AT方案治疗晚期乳腺癌的近期疗效及不良反应。方法 54例晚期乳腺癌患者随机分组,NE(盖诺联合表柔比星)组33例,AT(多西他赛联合表柔比星)组21例。化疗2个周期后评价疗效。结果 NE组与AT组总有效率分别为48.4%和47.4%,两组比较差异无统计学意义(P>0.05)。主要不良反应为消化道反应及血液学毒性,两组比较差异无统计学意义(P>0.05)。结论 NE方案和AT方案治疗晚期乳腺癌近期疗效肯定,不良反应可耐受。
Objective To observe the short-term curative effect and adverse reactions of NE and AT schemes in the treatment of advanced breast cancer. Methods A total of 54 cases of advanced breast cancer were randomly divided into NE group （vinorelbine and epirubicin, n=33） and AT group （docetaxel and epirubicin, n=21）. Curative effects were evaluated after 2 cycles of chemotherapy. Results The total effective rate of NE group and AT group were separately 48.4% and 47.4%. There was no significant difference between the two groups （P〉0.05）. The main adverse reactions were marrow suppression and gastrointestinal reaction, and the difference between the two groups was not statistically significant （P〉0.05）. Conclusion NE and AT schemes in the treatment of advanced breast cancer have certain short-term effects and tolerable adverse reactions.
出处
《中国实用医药》
2014年第29期50-51,共2页
China Practical Medicine
关键词
盖诺
多西他赛
表柔比星
晚期乳腺癌
Vinorelbine
Docetaxel
Epirubicin
Advanced breast cancer
